DIA EUROPE 2021

The clinical research landscape is changing and clinical trials are evolving to find new, faster and more efficient ways to bring new treatments to patients. The UK Life Sciences Industrial Strategy (August 2017) and the Life Sciences Sector Deal 2 (December 2018) set out the Government’s commitment to consolidate the UK as a world-leader in delivering clinical trials using novel or complex designs and/or innovative approaches to research delivery. The COVID19 pandemic has accelerated uptake and acceptance of this new era of clinical trials. This session will showcase a paradigm shift that is happening right now in the UK. It will examine where we were before the pandemic, compared to where we are now, and reveal how those rapid changes were made possible. It will also point to the future and consider the opportunities presented by the next generation of clinical trials.